Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), conducted stock sales totaling $111,415 on June 1, 2026. According to an SEC filing, the COO sold a total of 2,250 shares of common stock. These transactions were structured under a pre-arranged Rule 10b5-1 trading plan that had been adopted on December 9, 2025.
The weighted-average selling price for these shares ranged between $49.404 and $50.257 per share. The total value realized from the disposal of the 2,250 shares was reported as $111,415. The sales were comprised of two distinct transactions. In the first instance, Mr. Wassil sold 1,949 shares at a weighted-average price of $49.404 per share. The stated price for this initial lot represents a weighted average derived from various sale prices within a defined range. Separately, a second transaction accounted for the disposition of 301 shares, which were sold at a weighted-average price of $50.257 per share, also reflecting a weighted average across multiple sales.
Following these recent divestitures, Mr. Wassil's direct holdings in Vaxcyte common stock amount to 158,494 shares. While the company's current trading price is reported at $46.97, representing a 7% decline over the preceding week, the stock has shown considerable appreciation, having gained nearly 37% over the past year.
Beyond the insider activity, Vaxcyte Inc. remains active in its vaccine development pipeline and commercial visibility. The company reported achieving enrollment completion for two critical Phase 3 clinical trials concerning its 31-valent pneumococcal conjugate vaccine candidate, designated VAX-31. Specifically, the OPUS-1 trial involved a cohort of approximately 4,000 participants, while the OPUS-2 trial enrolled around 1,300 participants. These ongoing studies are designed to gather data supporting a planned Biologics License Application submission to the U.S. Food and Drug Administration (FDA).
Furthermore, Vaxcyte publicized findings from its VAX-31 Phase 1/2 study in the journal
Risks
More from Insider Trading